Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence

This systematic review evaluates the association between GLP-1 receptor agonists (medications used for diabetes and weight loss) and psychiatric manifestations including depression, suicidality, eating disorders, and substance use disorders. Evidence suggests modest antidepressant effects and potential therapeutic benefit in reward-regulation disorders, though concerns about suicidality remain unresolved and research is limited by small sample sizes and underrepresentation of people with psychiatric comorbidities.